|Title||Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.|
|Publication Type||Journal Article|
|Year of Publication||2016|
|Authors||Halper-Stromberg A, Nussenzweig MC|
|Journal||J Clin Invest|
Current antiretroviral drug therapies do not cure HIV-1 because they do not eliminate a pool of long-lived cells harboring immunologically silent but replication-competent proviruses - termed the latent reservoir. Eliminating this reservoir and stimulating the immune response to control infection in the absence of therapy remain important but unsolved goals of HIV-1 cure research. Recently discovered broadly neutralizing antibodies (bNAbs) exhibit remarkable breadth and potency in their ability to neutralize HIV-1 in vitro, and recent studies have demonstrated new therapeutic applications for passively administered bNAbs in vivo. This Review discusses the roles bNAbs might play in HIV-1 treatment regimens, including prevention, therapy, and cure.
|Alternate Journal||J. Clin. Invest.|
|PubMed Central ID||PMC4731188|
|Grant List||AI100148-03 / AI / NIAID NIH HHS / United States |
AI100663-04 / AI / NIAID NIH HHS / United States
AI109830-02 / AI / NIAID NIH HHS / United States
T32GM07739 / GM / NIGMS NIH HHS / United States
Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.